ARTICLE | Clinical News
Ocaliva obeticholic acid regulatory update
October 24, 2016 7:00 AM UTC
EMA’s CHMP recommended conditional approval of Ocaliva obeticholic acid from Intercept to treat primary biliary cholangitis as monotherapy in patients unable to tolerate ursodeoxycholic acid (UDCA) or...